What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
about
Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis.Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study.
P2860
What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
What do we know about treatmen ...... ion-resistant prostate cancer?
@en
type
label
What do we know about treatmen ...... ion-resistant prostate cancer?
@en
prefLabel
What do we know about treatmen ...... ion-resistant prostate cancer?
@en
P2093
P2860
P1476
What do we know about treatmen ...... ion-resistant prostate cancer?
@en
P2093
Alexandre de La Taille
François Audenet
Guillaume Ploussard
Julien Branchereau
Souhil Lebdai
Thibaut Murez
Thierry Lebret
Victor Basset
Vincent Flamand
Yann Neuzillet
P2860
P2888
P304
P356
10.1007/S00345-015-1687-0
P577
2015-09-15T00:00:00Z
P6179
1008075255